Table 1 Baseline demographic and clinical characteristics of the included patients with axial spondyloarthritis
Parameter | Non-radiographic axial SpA (n = 95) | Radiographic axial SpA (n = 115) | All patients (n = 210) |
|---|---|---|---|
Age, mean ± SD years | 38.7 ± 9.9 | 36.1 ± 11.0 | 37.3 ± 10.6 |
Symptom duration, mean ± SD years | 3.1 ± 2.2 | 5.0 ± 2.8 | 4.2 ± 2.7 |
Duration since diagnosis, mean ± SD years | 1.0 ± 1.3 | 2.0 ± 2.0 | 1.5 ± 1.8 |
Male sex, n (%) | 32 (33.7) | 75 (65.2) | 107 (51.0) |
HLA-B27 positive, n (%) | 69 (73.4) | 97 (84.3) | 166 (79.4) |
Peripheral arthritis, n (%) | 16 (16.8) | 15 (13.0) | 31 (14.8) |
Enthesitis†, n (%) | 23 (24.2) | 23 (20.0) | 46 (21.9) |
Uveitis, ever, n (%) | 15 (15.8) | 27 (23.5) | 42 (20.0) |
Psoriasis, ever, n (%) | 11 (11.6) | 17 (14.8) | 28 (13.3) |
Inflammatory bowel disease, ever, n (%) | 1 (1.1) | 3 (2.6) | 4 (1.9) |
Family history for SpA, n (%) | 16 (16.8) | 19 (16.5) | 35 (16.7) |
BASDAI, mean ± SD, 0–10 | 4.2 ± 2.0 | 3.8 ± 2.2 | 4.0 ± 2.1 |
BASFI, mean ± SD, 0–10 | 2.8 ± 2.2 | 3.0 ± 2.4 | 2.9 ± 2.3 |
Treatment with NSAIDs, n (%) | 65 (68.4) | 78 (67.8) | 143 (68.1) |
Treatment with csDMARDs, n (%) | 26 (28.6) | 35 (32.4) | 61 (30.7) |
Treatment with systemic steroids, n (%) | 6 (6.7) | 6 (5.6) | 12 (6.1) |
Treatment with a TNFα blocker, n (%) | 1 (1.1) | 4 (3.7) | 5 (2.5) |
Smoking, current, n (%) | 24 (25.3) | 39 (33.9) | 63 (30.0) |